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Abstract
This review summarizes the recent advances of osteoimmunology,
a new research field that investigates the interaction of the immune
system with the skeleton. Osteoimmunology has contributed signifi-
cantly to the understanding of joint destruction in rheumatoid arthritis
and other forms of arthropathies. In particular, the molecular regula-
tion of osteoclast formation and its control by proinflammatory
cytokines have helped investigators to understand the mechanisms
of bone erosion in rheumatic diseases. Osteoimmunology has also
allowed an improvement in our knowledge of the structure-sparing
effects of antirheumatic drug therapy. Moreover, recent advances
in the understanding of the molecular regulation of osteophyte
formation are based on the characterization of the regulation of
bone formation by inflammation. This review highlights the key
insights into the regulation of bone destruction and formation in
arthritis. Moreover, concepts of how bone influences the immune
system are discussed.
Introduction
Two major aspects determine the clinical picture of rheumatic
diseases. The first one is that inflammation is considered a
central component of many, especially the most severe, forms
of rheumatic diseases. Based on the observation of auto-
antibody formation and the accumulation of cells of the adaptive
immune system at sites of inflammation, some rheumatic
diseases, such as rheumatoid arthritis (RA), systemic lupus
erythematosus, or Sjögren syndrome, are considered to be
classic systemic autoimmune diseases. Chronic immune activa-
tion is regarded as a central triggering factor for inflammatory
rheumatic diseases. The second key aspect is how the
musculoskeletal tissue is affected, which is the common target
organ of this disease group. Musculoskeletal tissue experiences
progressive damage, which is the basis for a functional
impairment and a high disease burden. The combination of
chronic immune activation and musculoskeletal tissue damage
is the hallmark of rheumatic diseases. A detailed understanding
of the pathophysiological processes of rheumatic diseases thus
requires an understanding of the mutual interactions between
the immune system and musculoskeletal tissue.
Current concepts of osteoimmunology
Osteoimmunology is one of the areas that allow investigators to
gain novel insights into the crosstalk between the immune and
the musculoskeletal systems [1]. This field of research is par-
ticularly relevant to the understanding of rheumatic diseases,
which are characterized by profound alterations of bone
architecture aside from immune activation. The term osteo-
immunology is a rather novel one. It was created in the late
1990s after landmark observations demonstrating that T
lymphocytes triggered bone loss by inducing the differentiation
of bone-resorbing cells termed osteoclasts [2-4]. This concept
puts two, at first glance fundamentally different, organ systems –
the immune system and the skeleton – in much closer relation
to each other than one could ever expect.
Current concepts of osteoimmunology which are of relevance
to rheumatology involve (a) the regulation of bone degra-
dation by the immune system, (b) the interaction between
inflammation and bone formation, and (c) the role of bone and
bone marrow as a niche for immune cells, particularly plasma
cells (PCs). The first concept, immune-mediated regulation of
bone loss, has been studied intensively in recent years and
has become a well-developed concept that is instrumental in
the understanding of the different forms of bone loss in the
course of rheumatic diseases. In contrast, the second
concept, the molecular interactions between inflammation
and bone formation, is still much less developed but is
important in defining the mechanisms of repair of structural
damage in the joint as well as in explaining the patho-
physiology of bony ankylosis. Similarly, the third concept, the
bone marrow niche, is still incompletely understood but is
particularly relevant to the understanding of immune cell
trafficking during inflammatory diseases (that is, the triggers
for the recruitment of immune cells from the bone marrow into
the inflammatory sites) and to explaining the formation of a
stable microenvironment, which allows longevity and antibody
production by long-lived PCs.
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Osteoclasts as triggers of arthritic bone
erosions
Erosion of periarticular bone is a central feature of RA and
psoriatic arthritis [5,6]. Bone erosion mirrors a destructive
process in joints affected by arthritis as it reflects damage
triggered by chronic inflammation. Visualization of bone
erosions by imaging techniques is important not only for
diagnosing RA but also for defining severity of disease and
response to antirheumatic therapy [7]. Bone erosions require
the presence of osteoclasts in the joint as osteoclasts are the
only cell type capable of removing calcium from bone and,
therefore, of degrading bone matrix. Osteoclasts are part of
the inflamed synovial tissue of human RA and psoriatic
arthritis as well as of all major experimental models of arthritis.
Bromley and Woolley [8] and Gravallese and colleagues [9]
provided the first detailed description of osteoclasts in
inflamed joints in the late 1990s, showing that mature osteo-
clasts are localized at the site of bone erosion in RA joints.
Later, the essential function of osteoclasts in triggering
inflammatory bone erosions was shown by blocking essential
molecules for osteoclastogenesis or by using mice deficient
in osteoclasts [10,11]. In all of these models, no bone
erosions formed when osteoclasts were either effectively
blocked or genetically depleted, despite the presence of
synovial inflammation. These findings clearly showed that
osteoclasts are essential to the formation of bone erosions
and structural damage in inflamed joints.
Molecular and cellular mechanisms of
inflammatory bone erosion
What are the mechanisms leading to enhanced osteoclast
formation along joints? There are two key mechanisms that
are essential to the formation of osteoclasts in joints: first, the
accumulation of cells that serve as osteoclast precursors in
the joint, and, second, stimulation of differentiation of these
cells into the osteoclast lineage. Osteoclast precursors are
mononuclear cells belonging to the monocyte/macrophage
lineage [12]. Early monocytic precursor cells have the poten-
tial to differentiate into macrophages, dendritic cells, osteo-
clasts, and other more organ-specific cell lineage types such
as Kupffer cells in the liver or microglia in the brain. It is not
fully clear whether some monocytes entering an inflamed joint
are already committed to the osteoclast linage or ‘decide’
locally within the synovium upon receiving the appropriate
signals. Nonetheless, experimental evidence supports the
view that the peripheral monocytic pool changes during
inflammation. For instance, the fraction of CD11b+ cells that
serve as osteoclast precursors increases, suggesting that an
increased number of cells entering the joint can differentiate
into osteoclasts [13]. Moreover, cytokines such as tumor
necrosis factor (TNF) already induce the expression of
receptors on the surface of monocytes, which are important
for osteoclast differentiation. One of them is OSCAR
(osteoclast-associated receptor), an important costimulation
molecule for osteoclasts [14]. Much less is known about
surface receptors on monocytes, which can negatively
regulate their differentiation into osteoclasts. In fact, one such
molecule is CD80/CD86, which effectively blocks osteoclast
formation when bound to CTLA4, a negative regulator of T-
cell costimulation by monocytes [15,16]. This could link
regulatory T cells, which highly express CTLA4 on their
surface, to bone homeostasis as these cells can suppress
osteoclast formation independently of RANKL (receptor
activator of nuclear factor-kappa B ligand).
The second mechanism is that monocytic osteoclast pre-
cursors which have already entered the inflamed joints are
allowed to further differentiate into osteoclasts (Figure 1).
This process requires intensive crosstalk with other cells,
particularly with synovial fibroblast-like cells and activated
T cells. Among T cells, both TH1 and TH17 subsets are of
importance in this process. Both cell types inducibly express
RANKL, which is an essential stimulating signal for osteo-
clastogenesis and is also involved in the activation of mature
osteoclasts [3,17]. RANKL binds a surface receptor on the
precursor cells termed RANK, which induces signaling via
nuclear factor-kappa-B and the activation protein-1 trans-
cription factor family, which are important for osteoclast
differentiation [2,3]. This essential osteoclastogenic cytokine
is expressed in the synovium of patients with RA, suggesting
that it actively contributes to the formation of osteoclasts in
the synovium [18,19]. A high level of RANKL expression is
apparently not balanced by expression of regulatory
molecules such as osteoprotegerin (OPG), a decoy receptor
of RANKL which blocks osteoclast formation [20], suggest-
ing that this imbalance appears to be of importance in
yielding a negative net effect on local bone mass in the case
of arthritis. This concept is supported not only by data
obtained in animal models of arthritis showing effective
protection from structural damage when blocking RANKL
with OPG, but also by a recent clinical study showing that an
antibody  against RANKL (denosumab) provides protection
from the progression of structural damage in RA patients [21].
Apart from RANKL, the osteoclastogenic properties of the
inflamed synovial membrane are further enhanced by the
expression of macrophage colony-stimulating factor, which is
essential for osteoclast formation as well [22]. Moreover,
proinflammatory cytokines such as TNF and interleukin (IL)-1,
IL-6, and IL-17 are all potent inducers of RANKL expression
and thus enhance osteoclast differentiation as well. Some of
these cytokines additionally exert direct effects on osteoclast
precursors, and TNF, in particular, engages TNF-receptor
type I on the surface of osteoclast precursors, stimulating
their differentiation into osteoclasts [23]. This link between
proinflammatory cytokines and osteoclast formation most
likely explains why cytokine-targeted therapy, particularly
blockade of TNF, is highly effective in retarding structural
damage in RA. Thus, TNF-blocking agents virtually arrest
radiographic damage in RA and are considered excellent
agents for achieving structural protection of joints [24-29].
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which define the structure-sparing effect of tocilizumab in
addition to its well-established anti-inflammatory effect
[30,31], one can anticipate such an effect based on the
observation that IL-6 drives RANKL expression and thus
supports osteoclastogenesis [32].
Periarticular and systemic bone loss in
rheumatic disease
Periarticular bone loss has long been known as a
radiographic sign for RA and has been explained by paracrine
effects of the inflammatory tissue on periarticular bone. Still,
periarticular bone loss (also termed periarticular osteo-
porosis) has been poorly defined so far. Apparently, peri-
articular bone loss is based on a substantial decrease in
bone trabeculae along the metaphyses of bones close to
inflamed joints, suggesting that the bone marrow cavity along
inflamed joints is also part of the disease process of arthritis.
This is supported by data from magnetic resonance imaging
(MRI) studies in patients with RA which have unraveled a high
frequency of signal alterations in the juxta-articular bone
marrow in addition to synovitis outside the cortical bone
barrier [33,34]. These lesions are water-rich lesions which
have a low fat content, suggesting that bone marrow fat has
been locally replaced by water-rich tissue. Histological
examination of bone marrow lesions has been carried out in
joints of advanced-stage RA patients undergoing joint
replacement surgery. These studies have shown that bone
marrow lesions visualized in MRI contain (water-rich) vascu-
larized inflammatory infiltrates which replace bone marrow fat
and harbor aggregates of B cells and T cells. Importantly,
very similar, if not identical, MRI changes are found early in
the disease process of RA and have been shown to be linked
to subsequent bone erosions in the same joints [35]. Bone
marrow lesions are often linked to a cortical penetration of
inflammatory tissue either by means of bone erosions or by
small cortical bone channels which connect the synovium
with the juxta-articular bone marrow. Moreover, bone marrow
lesions are associated with an endosteal bone response as
they coincide with the accumulation of osteoblasts and the
deposition of bone matrix in the endosteum [36]. These novel
data have enhanced our view of arthritis as a disease that is
not solely confined to the synovial membrane but that extends
to bone marrow.
It has long been known that inflammatory diseases, including
RA and ankylosing spondylitis (AS), lead to osteoporosis and
increased fracture risk. Data obtained in recent years have
supported these concepts and have shed more light on
osteoporosis and fracture risk in RA patients. Osteopenia and
osteoporosis are frequent concomitant diseases in patients
with RA and are even observed in rather high frequency
before any disease-modifying antirheumatic drug or
glucocorticoid therapy is started. Roughly 25% of patients
with RA show an osteopenic bone mineral density at the
spine or hip before the onset of therapy in early RA patients,
and 10% have osteoporosis [37]. This suggests that RA
patients are at high risk to develop complications from
systemic bone loss as the prevalence of low bone mass is
already high at the onset of disease. The reasons for this
appear to be based on the coincidence of standard risk
factors for osteoporosis with the onset of RA such as higher
age and female gender. Another explanation is the possibility
that low-grade inflammation often long precedes the onset of
clinical symptoms of RA. Indeed, as independent population-
based studies have shown, even small elevations of
C-reactive protein as a sign of low-grade inflammation in the
normal healthy population dramatically increase fracture risk
[38]. Fracture risk is indeed higher in RA patients as it has
been confirmed by a recent meta-analysis of nine prospective
population-based cohorts which showed that fracture risk
doubles with the diagnosis of RA, regardless of whether
glucocorticoids are used or not [39]. Similarly, a large case
control study based on the British General Practice Research
Database has shown that RA doubles the risk of hip and
vertebral facture, clearly supporting the concept that inflam-
mation is an independent risk factor for osteoporosis [40].
Osteoimmunological aspects of bone
formation in rheumatic disease
To gain a balanced view of the interaction between the
immune system and bone, it is important to better define how
immune activation controls bone formation. Inflammatory
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Figure 1
Osteoclast formation in the joint. Monocytic cells in the synovium serve
as osteoclast precursors. Upon exposure to macrophage colony-
stimulating factor (MCSF) and RANKL synthesized by T cells and
synovial fibroblasts, osteoclasts fuse to polykaryons termed
preosteoclasts, which then undergo further differentiation into mature
osteoclasts, acquiring specific features such as the ruffled membrane.
Inflammatory cytokines such as tumor necrosis factor (TNF) and
interleukin (IL)-1, IL-6, and IL-17 increase the expression of RANKL
and thus support osteoclastogenesis in the joint. In contrast, regulatory
T (Treg) cells block osteoclast formation via CTLA4. RANKL, receptor
activator of nuclear factor-kappa B ligand.arthritides show profound differences in joint architecture.
These cover the whole spectrum; from an almost purely
erosive disease like RA, to a mixed pattern with concurrent
erosions and bone formation, and prominently bone-forming
patterns of disease as observed in AS. Given this obser-
vation, the regulation of bone formation becomes an interest-
ing aspect of rheumatic diseases. In RA, there is little sign of
repair of bone erosions, which is astonishing considering that
bone formation is usually coupled to bone resorption and
increased rate of bone resorption should this entail increased
bone formation. This, however, is by no means the case in
RA, which is virtually a purely erosive disease. Recent data
suggest that bone formation is actively suppressed by
inflammation. Interestingly, TNF potently suppresses bone
formation by enhancing the expression of dickkopf-1 (DKK1),
a protein that negatively regulates the Wnt signaling pathway
[41]. Wnt signals a key trigger for bone formation by
enhancing the differentiation of osteoblasts from their
mesenchymal cell precursors. Wnt proteins are also involved
in the regulation of osteoclastogenesis since they enhance
the expression of OPG and block osteoclast formation [42].
Thus, influencing the balance of Wnt proteins and their
inhibitors is a very potent strategy to disturb bone
homeostasis: Low levels of Wnt activity yield low bone
formation and high bone resorption, whereas high levels of
Wnt activity increase bone formation and simultaneously
block bone resorption. In RA, the former scenarios appear to
be relevant since bone resorption is increased and bone
formation is decreased. Inhibitors of Wnt, like DKK1, are
expressed in the synovial tissue of RA patients, suggesting
suppression of bone formation. This concept is further
supported by the paucity of fully differentiated osteoblasts
within arthritic bone erosions, which indicates that there is
indeed no major bone formation taking place in these lesions.
Pure degradation of bone during arthritis is rather the
exception than the rule in joint disease. Psoriatic arthritis, AS,
but also osteoarthritis and metabolic arthropathies such as
hemochromatosis arthropathy are partly or even pre-
dominantly characterized by bony spurs along joints and
intervertebral spaces. These lesions are based on new bone
formation. We have recently observed that osteophyte
formation cannot easily be compared with erosive structural
damage observed in RA and that therapies blocking bone
erosions such as TNF blockade do not influence the forma-
tion of osteophytes [43]. Areas that are prone to osteophyte
formation are (a) periarticular sites of the periosteum in the
vicinity of the articular cartilage, (b) edges of vertebral bodies,
and (c) the insertion sites of tendons. These sites are
particularly rich with fibro cartilage, which is considered a
tissue from which osteophyte formation emerges given that
certain triggering factors interact [44]. Triggers are certainly
mechanical factors since osteophytes often emerge at the
entheses along the insertion sites of the tendons. Usually,
osteophytes are based on endochondral ossification, which
first leads to differentiation of hypertrophic chondrocytes from
mesenchymal cells and abundant deposition of extracellular
matrix before rebuilding into bone occurs, which requires
differentiation of osteoblasts and deposition of bone. Mole-
cular signals involved in osteophyte formation have recently
been defined: Transforming growth factor-beta as well as
bone morphogenic proteins (BMPs) facilitate osteophyte
formation, and active BMP signaling through Smad3 proteins
has been demonstrated in human osteophyte formation [45].
Moreover, noggin, an inhibitor of BMPs, effectively blocks
osteophyte formation, suggesting that this protein family plays
a key role in the formation of bony spurs by facilitating
osteoblast differentiation [45]. Another essential protein
family involved in osteophyte formation is the Wnt protein
family. These proteins bind to surface receptors like LRP5/6
and frizzled proteins on the surface of mesenchymal cells,
leading to signaling through β-catenin, which translocates to
the nucleus and activated genes involved in bone formation.
Nuclear translocation of β-catenin is observed at sites of
bony spurs, suggesting its activation by Wnt proteins. There
appears to be tight crosstalk between Wnt protein and BMP
proteins as these two protein families act synergistically on
bone formation. Moreover, there are crosstalks to the
RANKL-OPG system, and Wnt proteins induce the
expression of OPG, which shuts down bone resorption [46].
It thus appears that the balance between bone-forming
factors such as Wnt and BMP proteins and bone-resorbing
factors such as RANKL and TNF is crucial to how a joint
remodels during arthritis.
Bone marrow as a niche for B-cell
differentiation and autoantibody formation
Osteoimmunology research in recent years has been domi-
nated by mechanisms that explain the influence of the
immune system on bone, but there are other areas in which
bone-immune interactions play an important role. Hemato-
poiesis in the bone marrow is thought to depend on special
microenvironments, known as niches, that maintain blood
cells. Although the identity of niches and the interaction of
blood cells are still poorly understood, they appear to be
important in early B-cell differentiation as well as survival of
long-lived B cells and PCs [47]. Both the earliest precursors,
pre-pro-B cells and end-stage B cells, PCs require CXC
chemokine ligand (CXCL) 12 to home to the bone marrow
(Figure 2). CXCL12-expressing cells are a small population of
bone marrow stromal cells that are scattered throughout
bone marrow and that are distinct from the cells expressing
IL-7 adjoining more mature pro-B cells [48]. These cells not
only allow homing of memory B cells and PCs to the bone
marrow but also provide survival signals that allow the
longevity of these cells and prevent apoptosis. Thus, long-
lived memory B cells and PCs are dependent not only on
affinity maturation but also on an acquired ability to survive.
Successful competition for survival niches thus appears to be
a key factor explaining the longevity of these cells. Apparently,
by means of CXCL12-induced chemotaxis, PCs traffic into
these survival niches in the bone marrow, where they produce
Arthritis Research & Therapy    Vol 11 No 1 Schett
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disturbed (which is seen in murine lupus models, where PCs
are unresponsive to CXCL12), a marked accumulation of
PCs in the spleen is observed [47]. Also, circulating B cells
might only become memory B cells if they find appropriate
survival conditionsoutside of restimulating secondary lymphoid
organs.
Conclusions
Osteoimmunology has considerably refined our insights into
the pathogenesis of rheumatic diseases, particularly arthritis.
We have begun to understand the molecular interactions
between immune activation and the skeletal system which link
inflammatory diseases with bone loss. Knowledge of these
pathways will allow us to tailor drug therapies to target
skeletal damage more specifically and thus more effectively.
In addition, further insights into the role of bone and bone
marrow in shaping immune responses, particularly in
maintaining PCs in the bone marrow niche, will open a new
perspective in autoimmune diseases.
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